ProPublica is tracking the financial ties between doctors and medical companies.
Top U.S. medical schools and teaching hospitals are failing to adequately enforce policies that prohibit or restrict faculty physicians from being paid by drug companies to give promotional speeches about their products.
A new federal plan will require drug and medical device companies to report all payments to U.S. physicians in 2013. The danger? As Minnesota discovered, some information submitted may not be accurate.
This week, Massachusetts became the first state to post an online database of payments from drug and medical device companies to the state’s health care providers.
A review of the highest-earning physicians in ProPublica’s Dollars for Docs database offers insight into why some medical professionals are drawn to the lucrative sideline of public speaking to promote favored drugs.
While it’s not illegal for doctors to promote prescription drugs and accept payments from drug companies, such arrangements do raise ethical questions that some institutions have found concerning enough to try to limit.
The stories ProPublica is publishing today on the drug industry are part of a broader effort to expand the possibilities of collaborative journalism.
Pharma companies are being accused in lawsuits of paying doctors to push off-label uses of their drugs or financially rewarding doctors for prescribing their brand-name medications.
A Consumer Reports survey has found that patients say they would be concerned about the quality of care they receive from a doctor who is paid to promote a drug. And they said they want to know about such payments.